181 related articles for article (PubMed ID: 27023593)
21. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.
McCormick AL; Wang L; Garcia-Diaz A; Macartney MJ; Webster DP; Haque T
Antivir Ther; 2015; 20(1):81-5. PubMed ID: 24621453
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.
Kliemann DA; Tovo CV; da Veiga AB; de Mattos AA; Wood C
World J Gastroenterol; 2016 Oct; 22(40):8910-8917. PubMed ID: 27833382
[TBL] [Abstract][Full Text] [Related]
23. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
[TBL] [Abstract][Full Text] [Related]
24. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank.
Sharafi H; Ghalamkari S; Hassanshahi A; Alavian SM
Microb Drug Resist; 2019 Sep; 25(7):1072-1079. PubMed ID: 31021305
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of pre-treatment hepatitis C virus NS5A resistance associated amino-acid substitutions in genotype 1A infected patients in Scotland.
Bradley-Stewart A; Goldstein E; MacLean A; Gunson R
J Clin Virol; 2018 Apr; 101():44-46. PubMed ID: 29414187
[TBL] [Abstract][Full Text] [Related]
26. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.
Margeridon-Thermet S; Le Pogam S; Li L; Liu TF; Shulman N; Shafer RW; Najera I
PLoS One; 2014; 9(8):e105569. PubMed ID: 25140696
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6.
Patiño-Galindo JÁ; Salvatierra K; González-Candelas F; López-Labrador FX
Antimicrob Agents Chemother; 2016 Apr; 60(4):2402-16. PubMed ID: 26856832
[TBL] [Abstract][Full Text] [Related]
28. Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.
Bagaglio S; Uberti-Foppa C; Messina E; Merli M; Hasson H; Andolina A; Galli A; Lazzarin A; Morsica G
Clin Microbiol Infect; 2016 Apr; 22(4):386.e1-386.e3. PubMed ID: 26706617
[TBL] [Abstract][Full Text] [Related]
29. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.
Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G
Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164
[TBL] [Abstract][Full Text] [Related]
30. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
Gottwein JM; Pham LV; Mikkelsen LS; Ghanem L; Ramirez S; Scheel TKH; Carlsen THR; Bukh J
Gastroenterology; 2018 Apr; 154(5):1435-1448. PubMed ID: 29274866
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
[TBL] [Abstract][Full Text] [Related]
33. Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions.
Bagaglio S; Messina E; Hasson H; Galli A; Uberti-Foppa C; Morsica G
Viruses; 2019 Feb; 11(2):. PubMed ID: 30754682
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
[TBL] [Abstract][Full Text] [Related]
36. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
[TBL] [Abstract][Full Text] [Related]
37. A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry.
Ahmed M; Pal A; Houghton M; Barakat K
ACS Infect Dis; 2016 Nov; 2(11):872-881. PubMed ID: 27933783
[TBL] [Abstract][Full Text] [Related]
38. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
[TBL] [Abstract][Full Text] [Related]
39. Update on hepatitis C virus resistance to direct-acting antiviral agents.
Poveda E; Wyles DL; Mena A; Pedreira JD; Castro-Iglesias A; Cachay E
Antiviral Res; 2014 Aug; 108():181-91. PubMed ID: 24911972
[TBL] [Abstract][Full Text] [Related]
40. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
